Esperion (ESPR) Q1 2026 earnings review
Vision 2040 Abandoned for a $3.16 Takeout as U.S. Growth Stalls
Esperion’s narrative has abruptly completely reversed. After quarters of touting a 'Vision 2040' independent path to blockbuster status and sustainable profitability, management has agreed to sell the company to Essence Parent Inc. for $3.16 per share in cash, plus a Contingent Value Right (CVR). The financials explain why: U.S. net product sales sequentially contracted slightly to $43.4M in Q1, breaking the growth momentum. Operating losses returned ($6.6M) as the Q4 milestone sugar-high wore off, and interest expenses continue to consume nearly $20M per quarter. In a concurrent surprise move, Esperion spent $75M upfront to acquire Corstasis and its nasal spray diuretic, Enbumyst, right before agreeing to be acquired themselves.
🐂 Bull Case
The $3.16 per share all-cash acquisition by Essence Parent Inc. provides a definite exit and a premium to the $2.50 per share public offering completed in October 2025. The CVR offers up to ~$0.39/share in potential upside.
The acquisition of Corstasis brings Enbumyst (FDA-approved nasal spray for congestive heart failure edema) into the portfolio, instantly diversifying Esperion away from pure LDL-C reliance.
🐻 Bear Case
U.S. product sales of NEXLETOL/NEXLIZET declined sequentially from $43.7M in 25Q4 to $43.4M in 26Q1. This decelerating trajectory contradicts prior management claims of an 'inflection point' and steady blockbuster momentum.
The company incurred $19.8M in interest expense this quarter alone. Even with rising revenues, the balance sheet was too toxic to sustain independence without further highly dilutive equity raises.
⚖️ Verdict: ⚪
Neutral. The standalone investment thesis is over. Esperion is now a merger-arbitrage play tied to the $3.16 cash consideration and the difficult-to-achieve CVR milestones.
Key Themes
The Takeout: Essence Parent Inc. Merger
On May 1, 2026, Esperion agreed to be acquired by Essence Parent Inc. for $3.16 per share in cash plus one CVR per share. The CVR pays out up to $100M total (~$0.39/share) if two milestones are hit: $40M if 2027 U.S. Bempedoic Acid sales exceed $300M-$350M, and $60M if U.S. Enbumyst sales exceed $160M in any year by 2030. This marks a total reversal of management's 'Vision 2040' standalone strategy heavily promoted in late 2025.
The Corstasis Pivot: Buying Before Selling
In a highly unusual sequence, on April 2, 2026 (a month before the Essence merger announcement), Esperion completed the acquisition of Corstasis for $75M in upfront cash, funded via a new $25M term loan draw and a $50M royalty sale to Athyrium. The prize is Enbumyst, an FDA-approved nasal spray loop diuretic. This aggressive expansion instantly strained liquidity right before the ultimate sale of the company.
U.S. Product Sales Plateau
Decelerating. A major red flag contradicting management's prior bullish narrative: U.S. net product sales were $43.4M, effectively flat/down from $43.7M in 25Q4. YoY growth compressed from 42% in 25Q2 to just 24% in 26Q1. This sequential stagnation suggests the 'statin-intolerant' market penetration is hitting heavy resistance, making the $300M CVR milestone for 2027 look highly precarious.
Material Weakness Remains Unremediated
The company disclosed that a material weakness regarding inventory and cost of sales balances at third-party contract manufacturers—originally identified in Q2 2025—is still not remediated as of March 31, 2026. This ongoing lack of internal control over physical inventory tracking is a glaring operational failure for a commercial-stage pharmaceutical company.
Macro Pressures Forced the Exit
The 10-Q explicitly highlights macroeconomic developments, inflationary pressures, and interest rate fluctuations limiting their ability to raise favorable capital. With $152.7M in high-yield Term Debt, $97.4M in Convertible Notes, and massive royalty sale liabilities, the $19.8M quarterly interest expense created an unsustainable cash burn in a 'higher for longer' rate environment, likely forcing the Board to accept a sale.
Generic ANDA Litigation Threat Looms
While Esperion settled with some generic filers (delaying entry to 2040), litigation remains ongoing against Sandoz, Aurobindo, MSN, and Renata. A trial is anticipated no earlier than January 2027. Any adverse ruling would obliterate the long-term value of the U.S. franchise.
International Collaboration Revenue
Stable. Ex-U.S. collaboration revenue continues to be a reliable source of cash flow, coming in at $36.7M for Q1 (+22% YoY). This was driven by $32.7M from Daiichi Sankyo Europe (DSE) and emerging contributions from Otsuka in Japan ($2.1M) following its late 2025 approval and NHI pricing.
Cardiovascular Risk Reduction Label
The expanded labels for NEXLETOL and NEXLIZET to include cardiovascular risk reduction (approved March 2024, updated Nov 2025) remain the core foundational driver for primary and secondary prevention prescriptions, though the Q1 sales data suggests the initial wave of adoption from this label expansion has normalized.
Global Market Access Expansion
Approvals are stacking up globally. Beyond Japan and Europe, supplemental NDAs are progressing in Canada (NEXLETOL approved Q4 2025, NEXLIZET expected H1 2026), Israel (expected H1 2026), and Australia (expected Q4 2026). This geographic expansion drives bulk tablet sales and eventual royalty streams.
Other KPIs
Reversing. Following a highly profitable Q4 2025 ($85.2M) fueled by a $90M Otsuka milestone, the core business returned to structural unprofitability. However, the operating loss is narrower than the $(22.1)M reported a year ago in Q1 2025, primarily due to higher gross profit on rising sales.
Accelerating. Up slightly from $19.4M YoY. This massive expense line item is driven by the $150M term loan and the imputing of interest on the $304.7M OMERS royalty sale liability. This line item single-handedly wiped out 43% of the company's Q1 Gross Profit ($45.5M).
Down from $167.9M at the end of 2025. Importantly, this March 31 balance does not include the subsequent April 2nd cash outflow of $75M for the Corstasis acquisition, nor the $75M in fresh capital (Term Loan + Athyrium royalty sale) raised the same day to fund it.
Guidance
Accelerating. Management expects SG&A to rise due to commercialization initiatives for the newly acquired ENBUMYST and expansion of the sales team, offsetting any prior cost-containment measures.
Stable. R&D expenses are expected to remain flat as the company continues its Phase III pediatric trial and progresses preclinical pipeline assets.
Key Questions
The Strategic Reversal
Just months ago, management touted 'Vision 2040' and sustainable profitability by early 2026. Why did the Board abruptly abandon the standalone plan to sell to Essence Parent for $3.16 per share?
U.S. Sales Stagnation
U.S. product sales were slightly down sequentially in Q1. Is this a one-time payer/deductible reset issue, or has the addressable 'statin-intolerant' market been fully penetrated?
Corstasis Deal Logic
Why execute a highly complex, debt-and-royalty-funded $75M acquisition of Corstasis just weeks before selling the entire company? Was the Enbumyst asset a requirement from Essence Parent for the merger?
Inventory Control Failures
The material weakness regarding inventory at contract manufacturers has been unresolved since Q2 2025. What specific roadblocks are preventing the remediation of these basic operational controls?